Company Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Real-time Euronext Paris 12:35:18 2024-03-28 pm EDT 5-day change 1st Jan Change
3.637 EUR +1.28% Intraday chart for Valneva +7.83% -22.94%

Business Summary

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

Valneva SE has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure.

Revenues from its growing commercial business help fuel the continued advancement of Valneva SE's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Number of employees: 676

Sales per Business

EUR in Million2022Weight2023Weight Delta
Development and Commercialization of Prophylactic Vaccines
100.0 %
- - 154 100.0 % -

Sales per region

EUR in Million2022Weight2023Weight Delta
United States
21.4 %
-24 -6.6 % 33 21.4 % -238.49%
Canada
18.3 %
19 5.2 % 28 18.3 % +49.14%
United Kingdom
13.2 %
181 50.2 % 20 13.2 % -88.81%
Rest of World
10.6 %
17 4.8 % 16 10.6 % -6.06%
Austria
9.5 %
21 5.9 % 15 9.5 % -30.92%
Germany
8.8 %
69 19.0 % 14 8.8 % -80.30%
Nordics
8.3 %
12 3.3 % 13 8.3 % +5.69%
Other Europe
6.1 %
19 5.2 % 9 6.1 % -50.19%
France
3.8 %
47 12.9 % 6 3.8 % -87.39%

Managers

Managers TitleAgeSince
Chief Executive Officer 60 13-05-09
Director of Finance/CFO 54 21-07-28
Chief Operating Officer - 21-07-05
Chief Tech/Sci/R&D Officer 53 20-09-30
Investor Relations Contact - 13-05-31
Corporate Officer/Principal - 22-11-16
General Counsel 60 17-03-31
Corporate Officer/Principal 58 13-05-09

Members of the board

Members of the board TitleAgeSince
Director/Board Member - 23-06-20
Director/Board Member 73 13-03-06
Director/Board Member 59 22-06-23
Chief Executive Officer 60 13-05-09
Director/Board Member 60 22-06-23
Director of Finance/CFO 54 21-07-28
Chairman 62 13-03-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 138,912,142 115,154,909 ( 82.90 %) 124,322 ( 0.0895 %) 82.89 %
Stock B 0 20,514 0 0

Shareholders

NameEquities%Valuation
Groupe Grimaud La Corbière SA
8.735 %
12,132,158 8.735 % 40 M €
9,549,761 6.875 % 32 M €
Bpifrance Participations SA /PRIVATE EQUITY/
6.220 %
8,639,886 6.220 % 29 M €
Deep Track Capital LP
5.419 %
7,526,807 5.419 % 25 M €
CDC Croissance SA
1.490 %
2,069,552 1.490 % 7 M €
Medical Strategy GmbH
1.129 %
1,568,808 1.129 % 5 M €
Apo Asset Management GmbH
0.4840 %
672,317 0.4840 % 2 M €
635,218 0.4573 % 2 M €
385,545 0.2776 % 1 M €
HSBC Global Asset Management (France) SA
0.2314 %
321,408 0.2314 % 1 M €
NameEquities%Valuation
General American Investors Co., Inc. (13F)
0.4968 %
345,000 0.4968 % 2 M €
LifeSci Fund Management LLC
0.0494 %
34,298 0.0494 % 243 516 €
Alphacentric Advisors LLC
0.0494 %
34,298 0.0494 % 243 516 €
Morgan Stanley & Co. International Plc
0.006278 %
4,360 0.006278 % 30 956 €
Wells Fargo Clearing Services LLC
0.003629 %
2,520 0.003629 % 17 892 €
Barclays Capital Securities Ltd.
0.000600 %
417 0.000600 % 2 961 €
Arbor Point Advisors LLC
0.000216 %
150 0.000216 % 1 065 €
Qube Research & Technologies Ltd. (France)
0.000032 %
22 0.000032 % 156 €
RBC CMA LLC
0.000029 %
20 0.000029 % 142 €

Holdings

NameEquities%Valuation
124,322 0.09% 412,619 $

Company contact information

Valneva SE

Campus Bio-Ouest 6, rue Alain Bombard

44800, Saint-Herblain

+33 2 28 07 37 10

http://www.valneva.com
address Valneva(VLA)

Group companies

NameCategory and Sector
Miscellaneous Commercial Services
Biotechnology